EP
QTTB icon

Essential Partners’s Q32 Bio QTTB Stock Holding History

Essential Partners’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5
Closed -$7 – 2808
2025
Q2 		$7 Buy
+5
New +$9 ﹤0.01% 2266

Other funds holding QTTB

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
TOCUITCONY
Trustees of Columbia University in the City of New York New York $468M AUM 20.53% 1-Year Est. Return

Essential Partners's QTTB Position: Q3 2025 in Review

Essential Partners sold out of Q32 Bio (QTTB) in Q3 2025, closing a stake of 5 shares — an estimated $7 sold.

Essential Partners first reported a position in QTTB in Q2 2025 and held it in 1 quarter. The position peaked at $7 in Q2 2025. 53 funds tracked by Wall St. Rank hold QTTB as of Q3 2025.

  • Essential Partners reported no remaining Q32 Bio position as of Q3 2025 after selling out during the quarter.
  • Essential Partners sold 5 Q32 Bio shares in Q3 2025, an estimated $7.
  • Essential Partners first reported a position in Q32 Bio in Q2 2025 and held it in 1 quarter.
  • Essential Partners's Q32 Bio position peaked at $7 in Q2 2025.
  • 53 funds tracked by Wall St. Rank held Q32 Bio as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.